RESUMO
Background: The treatment of minimal change disease (MCD) consists of a high dose of steroids for several months, implying significant drug toxicity. Nevertheless, relapses of steroid-sensitive MCD usually respond to lower doses of steroids. Methods: The objective of this study was to analyze whether a low dose of steroids (LDS) is effective for the treatment of MCD relapses. Since 2018, new relapses of steroid-sensitive adult patients with MCD in three Spanish centers have been treated with LDS. The cumulative dose of steroids, the time to remission, and the relapse-free time were compared between relapses treated with LDS and previous relapses of the same patients treated with a standard dose of steroids (SDS). Results: A total of 51 relapses in 31 patients were treated with LDS and compared with 48 historical relapses of the same patients treated with SDS. The mean doses of prednisone adjusted by weight for the initial treatment were 0.45 mg/kg (0.40-0.51 mg/kg) in the relapses treated with LDS and 0.88 mg/kg (0.81-1.00 mg/kg) in those treated with SDS. The mean cumulative doses of prednisone in LDS- and SDS-treated relapses were 1,191 mg (801-1,890 mg) and 3,700 mg (2,755-5,800 mg), respectively. The duration of treatment was 63 days (42-117 days) in the LDS group and was 140 days (65-195 days) in the SDS group. All patients achieved complete remission within 1 month after steroid therapy in both groups. The times to remission of the LDS and SDS groups were 19.10 ± 12.80 and 18.93 ± 12.98 days, respectively (p = 0.95). Conclusion: Among the steroid-sensitive patients with MCD, relapse therapy with LDS (0.5 mg/kg) appears effective and allows minimization of the steroid cumulative dose.
RESUMO
Artificial intelligence (AI) is a science that involves creating machines that can imitate human intelligence and learn. AI is ubiquitous in our daily lives, from search engines like Google to home assistants like Alexa and, more recently, OpenAI with its chatbot. AI can improve clinical care and research, but its use requires a solid understanding of its fundamentals, the promises and perils of algorithmic fairness, the barriers and solutions to its clinical implementation, and the pathways to developing an AI-competent workforce. The potential of AI in the field of nephrology is vast, particularly in the areas of diagnosis, treatment and prediction. One of the most significant advantages of AI is the ability to improve diagnostic accuracy. Machine learning algorithms can be trained to recognize patterns in patient data, including lab results, imaging and medical history, in order to identify early signs of kidney disease and thereby allow timely diagnoses and prompt initiation of treatment plans that can improve outcomes for patients. In short, AI holds the promise of advancing personalized medicine to new levels. While AI has tremendous potential, there are also significant challenges to its implementation, including data access and quality, data privacy and security, bias, trustworthiness, computing power, AI integration and legal issues. The European Commission's proposed regulatory framework for AI technology will play a significant role in ensuring the safe and ethical implementation of these technologies in the healthcare industry. Training nephrologists in the fundamentals of AI is imperative because traditionally, decision-making pertaining to the diagnosis, prognosis and treatment of renal patients has relied on ingrained practices, whereas AI serves as a powerful tool for swiftly and confidently synthesizing this information.
RESUMO
En vista de la alta prevalencia del cáncer de próstata en la población venezolana y la ausencia de un patrón genético conocido en relación a la expresión de las enzimas Glutatión S-transferasas, se estudió la relación entre la expresión de un polimorfismo nulo de estas enzimas y la presencia de cáncer de adenocarcinoma prostática Métodos: Se incluyen 100 individuos para el muestreo no probabilístico, 50 pacientes con diagnóstico de adenocarcinoma de próstata comprobado mediante biopsia y 50 controles con hiperplasia prostática benigna demostrada mediante tacto y corroborada por ultrasonido transrectal, provenientes de los principales hospitales del país, se procedió a tomar muestra de sangre y mediante reacción de cadena de polimerasa, se determinó la presencia o ausencia de los genes para las enzimas Glutatión S-transferasa Mu 1 (GST M) y glutatión S-transferasa theta 1 (GST T1). Resultados: se logró evidenciar que el genotipo nulo se encontró en 40 y 24% de los pacientes mientras que para los controles fue de 38% y 22% respectivamente, demostrando que en la población venezolana estudiada no existen diferencias significativas entre casos y controles. Conclusiones: No se pudo demostrar una diferencia significativa entre los dos grupos estudiados. Recomendaciones: A pesar de nuestros hallazgos, se necesitan estudios futuros con muestras de mayor tamaño para dilucidar la posible asociación entre este patrón enzimático con el riesgo de presentar cáncer de próstata(AU)
Prostate cancer presents with a high incidence in the Venezuelan population. there is no known genetic pattern related to the expression of drug metabolizing enzymes Glutathione S-transferases. Methods: We proceeded to study the possible correlation between null polymorphism for these enzymes and prostate adenocarcinoma. the sample included 100 patients recruited from the Urology Department of three University Hospitals in Caracas, Venezuela, 50 cancer patients and 50 cancer free controls. Blood samples were drawn from each patient and polymorphisms for Glutathione S-transferase Mu 1 (GST M1) and Glutathione-sS-transferase theta 1(GST T1) were determined by polymerase chain reaction from lymphocytes. Results: Null genotype was found in 40% and 24% of cancer patients whereas the percentage in controls was 38 and 22% respectively, showing no statistically significant differences between the two groups. Conclusions: It was not possible to show a significant difference between the two groups. Recommendations: Due to the small size of the sample, it would be necessary to explore further in a larger population sample to determine whether there is an association between the expression of these enzymes and prostate cancer(AU)
Assuntos
Humanos , Masculino , Hiperplasia Prostática/diagnóstico , Neoplasias da Próstata/enzimologia , Neoplasias da Próstata/patologia , Antígeno Prostático Específico , Ultrassom Focalizado Transretal de Alta Intensidade/métodos , Glutationa TransferaseRESUMO
Anamnesis: a colt showing a whitish coloration accompanied by abundant secretion on the left eye was examined. Clinical and laboratory findings: at ophthalmological examination, signs of melting ulcer were observed. Culture isolation revealed positive growing of Flavobacterium sp. and Gram-negative rods. Treatment approach: several keratectomies and tarsorrhaphies, as well as exhaustive antiproteinases, antiinflammatory, and antibiotic treatments, were conducted. Treatment focused on reducing inflammatory response, eliminating infective organisms, and promoting epithelial healing. Colt showed complete recovery of vision after 3 months. Conclusions: clinical management of melting ulcer implies exhaustive, though unexpensive, treatment.
Anamnesis: se examinó un potro que presentó una coloración blanquecina acompañada de abundante secreción en el ojo izquierdo. Hallazgos clínicos y de laboratorio: al examen oftalmológico se observaron signos de ulcera fundente. El aislamiento por cultivo mostró crecimiento de Flavobacterium sp. y cocos Gram negativos. Abordaje terapéutico: se realizaron varias queratectomías y tarsorrafias, además de un tratamiento exhaustivo con antiproteinasas, antiinflamatorios y antibióticos enfocado a reducir la respuesta inflamatoria, eliminar los microorganismos infecciosos y promover la cicatrización epitelial. 3 meses después, el potro mostró recuperación completa de la visión. Conclusiones: el manejo clínico de la úlcera fundente es demandante, pero no es un tratamiento costoso.
Antecedentes: foi examinado um potro que apresentava uma coloração esbranquiçada acompanhada por abundante secreção no olho esquerdo. Achados clínicos e de laboratório: ao exame oftalmológico foram encontrados sinais de úlcera colagenolítica. O isolamento por cultura apresentou crescimento de Flavobacterium sp. e cocos Gram negativos. Abordagem terapêutica: foram realizadas várias ceratectomias e tarsorrafias, além da instauração de um tratamento exaustivo com antiproteinases, anti-inflamatórios e antibióticos voltado para a redução da resposta inflamatória, a remoção de micro-organismos infecciosos e a estimulação da cicatrização epitelial. 3 meses depois o potro apresentou completa recuperação da visão. Conclusões: o manejo clínico da úlcera colagenolítica é exigente, mas não é um tratamento caro.